Sfoglia per Autore
Idiopathic erythrocytosis: a germline disease?
2024 Elli, E; Mauri, M; D’Aliberti, D; Crespiatico, I; Fontana, D; Redaelli, S; Pelucchi, S; Spinelli, S; Manghisi, B; Cavalca, F; Aroldi, A; Ripamonti, A; Ferrari, S; Palamini, S; Mottadelli, F; Massimino, L; Ramazzotti, D; Cazzaniga, G; Piperno, A; Gambacorti-Passerini, C; Piazza, R
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis
2024 Crespiatico, I; Zaghi, M; Mastini, C; D'Aliberti, D; Mauri, M; Mercado, C; Fontana, D; Spinelli, S; Crippa, V; Inzoli, E; Manghisi, B; Civettini, I; Ramazzotti, D; Sangiorgio, V; Gengotti, M; Brambilla, V; Aroldi, A; Banfi, F; Barone, C; Orsenigo, R; Riera, L; Riminucci, M; Corsi, A; Breccia, M; Morotti, A; Cilloni, D; Roccaro, A; Sacco, A; Stagno, F; Serafini, M; Mottadelli, F; Cazzaniga, G; Pagni, F; Chiarle, R; Azzoni, E; Sessa, A; Gambacorti Passerini, C; Elli, E; Mologni, L; Piazza, R
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease
2023 Caserta, C; Nucera, S; Barcella, M; Fazio, G; Naldini, M; Pagani, R; Pavesi, F; Desantis, G; Zonari, E; D'Angio, M; Capasso, P; Lombardo, A; Merelli, I; Spinelli, O; Rambaldi, A; Ciceri, F; Silvestri, D; Valsecchi, M; Biondi, A; Cazzaniga, G; Gentner, B
BEYOND THE TUMOUR: CHILDHOOD CANCER PREDISPOSING SYNDROMES [Guardare oltre il tumore: le cancer-predisposingsyndrome in età pediatrica]
2023 Bettini, L; Lauriola, R; Vendemini, F; Coliva, T; Biondi, A; Cazzaniga, G
Antibody Deficiency in Patients with Biallelic KARS1 Mutations
2023 Saettini, F; Guerra, F; Fazio, G; Bugarin, C; Mcmillan, H; Ohtake, A; Ardissone, A; Itoh, M; Giglio, S; Cappuccio, G; Giardino, G; Romano, R; Quadri, M; Gasperini, S; Moratto, D; Chiarini, M; Akira, I; Fukuhara, Y; Hayakawa, I; Okazaki, Y; Mauri, M; Piazza, R; Cazzaniga, G; Biondi, A
Correction to: Antibody Deficiency in Patients with Biallelic KARS1 Mutations (Journal of Clinical Immunology, (2023), 43, 8, (2115-2125), 10.1007/s10875-023-01584-7)
2023 Saettini, F; Guerra, F; Fazio, G; Bugarin, C; Mcmillan, H; Ohtake, A; Ardissone, A; Itoh, M; Giglio, S; Cappuccio, G; Giardino, G; Romano, R; Quadri, M; Gasperini, S; Moratto, D; Chiarini, M; Ishiguro, A; Fukuhara, Y; Hayakawa, I; Okazaki, Y; Mauri, M; Piazza, R; Cazzaniga, G; Biondi, A
Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement
2023 Bomken, S; Enshaei, A; Schwalbe, E; Mikulasova, A; Dai, Y; Zaka, M; Fung, K; Bashton, M; Lim, H; Jones, L; Karataraki, N; Winterman, E; Ashby, C; Attarbaschi, A; Bertrand, Y; Bradtke, J; Buldini, B; Burke, G; Cazzaniga, G; Gohring, G; De Groot-Kruseman, H; Haferlach, C; Nigro, L; Parihar, M; Plesa, A; Seaford, E; Sonneveld, E; Strehl, S; Van der Velden, V; Rand, V; Hunger, S; Harrison, C; Bacon, C; Van Delft, F; Loh, M; Moppett, J; Vormoor, J; Walker, B; Moorman, A; Russell, L
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial
2023 Hunger, S; Tran, T; Saha, V; Devidas, M; Valsecchi, M; Gastier-Foster, J; Cazzaniga, G; Reshmi, S; Borowitz, M; Moorman, A; Heerema, N; Carroll, A; Martin-Regueira, P; Loh, M; Raetz, E; Schultz, K; Slayton, W; Cario, G; Schrappe, M; Silverman, L; Biondi, A
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia
2023 Oikonomou, A; Valsecchi, L; Quadri, M; Watrin, T; Scharov, K; Procopio, S; Tu, J; Vogt, M; Savino, A; Silvestri, D; Valsecchi, M; Biondi, A; Borkhardt, A; Bhatia, S; Cazzaniga, G; Fazio, G; Bardini, M; Palmi, C
Hematopoietic Stem Cell (HSC)-Independent Progenitors Are Susceptible to Mll-Af9-Induced Leukemic Transformation
2023 Barone, C; Orsenigo, R; Cazzola, A; D'Errico, E; Patelli, A; Quattrini, G; Vergani, B; Bombelli, S; De Marco, S; D'Orlando, C; Bianchi, C; Leone, B; Meneveri, R; Biondi, A; Cazzaniga, G; Rabbitts, T; Brunelli, S; Azzoni, E
Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia
2023 Palmi, C; Bresolin, S; Junk, S; Fazio, G; Silvestri, D; Zaliova, M; Oikonomou, A; Scharov, K; Stanulla, M; Moericke, A; Zimmermann, M; Schrappe, M; Buldini, B; Bhatia, S; Borkhardt, A; Saitta, C; Galbiati, M; Bardini, M; Lo Nigro, L; Conter, V; Valsecchi, M; Biondi, A; Te Kronnie, G; Cario, G; Cazzaniga, G
Minimal Residual Disease Analysis by Monitoring Immunoglobulin and T-Cell Receptor Gene Rearrangements by Quantitative PCR and Droplet Digital PCR
2022 Starza, I; Eckert, C; Drandi, D; Cazzaniga, G
HDAC6 inhibition decreases leukemic stem cell expansion driven by Hedgehog hyperactivation by restoring primary ciliogenesis
2022 Pezzotta, A; Gentile, I; Genovese, D; Totaro, M; Battaglia, C; Leung, A; Fumagalli, M; Parma, M; Cazzaniga, G; Fazio, G; Alcalay, M; Marozzi, A; Pistocchi, A
Potential role of STAG1 mutations in genetic predisposition to childhood hematological malignancies
2022 Saitta, C; Rebellato, S; Bettini, L; Giudici, G; Panini, N; Erba, E; Massa, V; Auer, F; Friedrich, U; Hauer, J; Biondi, A; Fazio, G; Cazzaniga, G
Recurrent Germline Variant in RAD21 Predisposes Children to Lymphoblastic Leukemia or Lymphoma
2022 Schedel, A; Friedrich, U; Morcos, M; Wagener, R; Mehtonen, J; Watrin, T; Saitta, C; Brozou, T; Michler, P; Walter, C; Forsti, A; Baksi, A; Menzel, M; Horak, P; Paramasivam, N; Fazio, G; Autry, R; Frohling, S; Suttorp, M; Gertzen, C; Gohlke, H; Bhatia, S; Wadt, K; Schmiegelow, K; Dugas, M; Richter, D; Glimm, H; Heinaniemi, M; Jessberger, R; Cazzaniga, G; Borkhardt, A; Hauer, J; Auer, F
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease
2022 Zuna, J; Hovorkova, L; Krotka, J; Koehrmann, A; Bardini, M; Winkowska, L; Fronkova, E; Alten, J; Koehler, R; Eckert, C; Brizzolara, L; Trkova, M; Stuchly, J; Zimmermann, M; De Lorenzo, P; Valsecchi, M; Conter, V; Stary, J; Schrappe, M; Biondi, A; Trka, J; Zaliova, M; Cazzaniga, G; Cario, G
Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse
2022 Antic, Z; Yu, J; Bornhauser, B; Lelieveld, S; van der Ham, C; van Reijmersdal, S; Morgado, L; Elitzur, S; Bourquin, J; Cazzaniga, G; Eckert, C; Camos, M; Sutton, R; Cave, H; Moorman, A; Sonneveld, E; Geurts van Kessel, A; van Leeuwen, F; Hoogerbrugge, P; Waanders, E; Kuiper, R
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD)
2022 Locatelli, F; Lo Nigro, L; Andriano, N; Buldini, B; Silvestri, D; Villa, T; Parasole, R; Barisone, E; Testi, A; Biondi, A; Valsecchi, M; Rizzari, C; Conter, V; Basso, G; Cazzaniga, G
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium
2022 Buchmann, S; Schrappe, M; Baruchel, A; Biondi, A; Borowitz, M; Campbell, M; Cario, G; Cazzaniga, G; Escherich, G; Harrison, C; Heyman, M; Hunger, S; Kiss, C; Liu, H; Locatelli, F; Loh, M; Manabe, A; Mann, G; Pieters, R; Pui, C; Rives, S; Schmiegelow, K; Silverman, L; Stary, J; Vora, A; Brown, P
Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia
2022 Ramos-Muntada, M; Trincado, J; Blanco, J; Bueno, C; Rodriguez-Cortez, V; Bataller, A; Lopez-Millan, B; Schwab, C; Ortega, M; Velasco, P; Blanco, M; Nomdedeu, J; Ramirez-Orellana, M; Minguela, A; Fuster, J; Cuatrecasas, E; Camos, M; Ballerini, P; Escherich, G; Boer, J; Denboer, M; Hernandez-Rivas, J; Calasanz, M; Cazzaniga, G; Harrison, C; Menendez, P; Molina, O
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile